Cirrhosis/Liver Failure News

SAN FRANCISCO — Patients with advanced hepatocellular carcinoma with Child-Pugh B status experienced encouraging efficacy and safety outcomes after treatment with PD-1 inhibitor Opdivo, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Individuals with decompensated cirrhosis who underwent bariatric surgery experienced poorer survival outcomes than those with compensated cirrhosis and individuals who did not undergo this surgery, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Although previously reported effective at a 3 mg dose, NGM282 showed similar efficacy in treating nonalcoholic steatohepatitis at 1 mg, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Starting this weekend, Healio Gastroenterology and Liver Disease will provide live coverage from The Liver Meeting 2018.

Recent research into liver cirrhosis has focused on identifying factors that may prevent progression from earlier stages of fibrosis along with improving care for patients once diagnosed, as there is no curative therapy.

The incidence of alcohol-related liver cirrhosis among patients identified as high-risk ranged from 7% to 16% after approximately a decade of heavy drinking, and many patients had health care contact for alcohol misuse prior to diagnosis, according to results from a recently published study.

PHILADELPHIA — The 30-day readmission rate among patients with cirrhosis was 55% in a recent study and was tied to short hospital length of stay, as presented at the American College of Gastroenterology Annual Meeting.

This year at the American College of Gastroenterology Annual Meeting, several hepatology specialists discussed the changing landscape of liver disease health care, such as increasing rates of nonalcoholic fatty liver disease which is quickly becoming the number one indication for liver transplantation.

PHILADELPHIA – Black patients were more likely to be waitlisted with acute liver failure, require status-1 listing and undergo liver transplantation than white patients, according to a presentation at the American College of Gastroenterology Annual Meeting.

PHILADELPHIA — Treatment with rifaximin significantly reduced the risk for overt hepatic encephalopathy among patients with cirrhosis regardless of Child-Pugh class and was overall safe and well-tolerated, according to a presentation at the American College of Gastroenterology Annual Meeting.